Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

Bookmark and Share
Published: 8 Oct 2019
Views: 837
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Dr Maria Alsina speaks to ecancer at ESMO 2019 in Barcelona about quality of life results from the KEYNOTE-062 study.

The study looked at pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced gastric or gastroesophageal junction cancer.

Dr Alsina says the study demonstrated that giving the patients pembrolizumab is not inferior to giving them the standard chemotherapy with regards to quality of life.